Multimodal characterization of dilated cardiomyopathy: Geno- And Phenotyping of PrImary Cardiomyopathy (GrAPHIC).
DCM
Dilated cardiomyopathy
Genetic cardiomyopathy
Heart failure
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
15 Nov 2023
15 Nov 2023
Historique:
revised:
23
08
2023
received:
11
04
2023
accepted:
15
09
2023
pubmed:
15
11
2023
medline:
15
11
2023
entrez:
15
11
2023
Statut:
aheadofprint
Résumé
Cardiomyopathies (CMPs) are a heterogeneous group of diseases that are defined by structural and functional abnormalities of the cardiac muscle. Dilated cardiomyopathy (DCM), the most common CMP, is defined by left ventricular dilation and impaired contractility and represents a common cause of heart failure. Different phenotypes result from various underlying genetic and acquired causes with variable effects on disease development and progression, prognosis, and response to medical treatment. Current treatment algorithms do not consider these different aetiologies, due to lack of insights into treatable drivers of cardiac failure in patients with DCM. Our study aims to precisely phenotype and genotype the various subtypes of DCM and hereby lay the foundation for individualized therapy. The Geno- And Phenotyping of PrImary Cardiomyopathy (GrAPHIC) is a currently ongoing prospective observational monocentric cohort study that recruits patients with DCM after exclusion of other causes such as coronary artery disease, valvular dysfunction, myocarditis, exposure to toxins, and peripartum CMP. Patients are enrolled at our heart failure outpatient clinic or during hospitalization at the University Hospital Hamburg. Clinical parameters, multimodal imaging and functional assessment, cardiac biopsies, and blood samples are obtained to enable an integrated genomic, functional, and biomarker analysis. The GrAPHIC will contribute to a better understanding of the heterogeneous nature of primary CMPs focusing on DCM and provide improved prognostic approaches and more individualized therapies.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : European Union
ID : 241544
Organisme : AbbVie
Organisme : German Center for Cardiovascular Research
ID : FKZ 81X3710112
Informations de copyright
© 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: A position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008;29:270-276. doi:10.1093/eurheartj/ehm342
Seferović PM, Polovina M, Bauersachs J, Arad M, Gal TB, Lund LH, et al. Heart failure in cardiomyopathies: A position paper from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019;21:553-576. doi:10.1002/ejhf.1461
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2021;42:3599-3726. doi:10.1093/eurheartj/ehab368
Oechslin E, Jenni R. Left ventricular non-compaction revisited: A distinct phenotype with genetic heterogeneity? Eur Heart J 2011;32:1446-1456. doi:10.1093/eurheartj/ehq508
Reichart D, Magnussen C, Zeller T, Blankenberg S. Dilated cardiomyopathy: From epidemiologic to genetic phenotypes: A translational review of current literature. J Intern Med 2019;286:362-372. doi:10.1111/joim.12944
Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Böhm M, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2016;37:1850-1858. doi:10.1093/eurheartj/ehv727
Hershberger RE, Cowan J, Jordan E, Kinnamon DD. The complex and diverse genetic architecture of dilated cardiomyopathy. Circ Res 2021;128:1514-1532. doi:10.1161/CIRCRESAHA.121.318157
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145:e895-e1032. doi:10.1161/CIR.0000000000001063
de Boer RA, Heymans S, Backs J, Carrier L, Coats AJS, Dimmeler S, et al. Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: From molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC). Eur J Heart Fail 2022;24:406-420. doi:10.1002/ejhf.2414
Tschöpe C, Elsanhoury A. Treatment of transthyretin amyloid cardiomyopathy: The current options, the future, and the challenges. J Clin Med 2022;11:2148. doi:10.3390/jcm11082148
Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2021;42:1554-1568. doi:10.1093/eurheartj/ehab072
Kirchhof P, Sipido KR, Cowie MR, Eschenhagen T, Fox KAA, Katus H, et al. The continuum of personalized cardiovascular medicine: A position paper of the European Society of Cardiology. Eur Heart J 2014;35:3250-3257. doi:10.1093/eurheartj/ehu312
Guzzo-Merello G, Segovia J, Dominguez F, Cobo-Marcos M, Gomez-Bueno M, Avellana P, et al. Natural history and prognostic factors in alcoholic cardiomyopathy. JACC Heart Fail 2015;3:78-86. doi:10.1016/j.jchf.2014.07.014
Barutaut M, Fournier P, Peacock WF, Evaristi MF, Caubère C, Turkieh A, et al. Insulin-like growth factor binding protein 2 predicts mortality risk in heart failure. Int J Cardiol 2020;300:245-251. doi:10.1016/j.ijcard.2019.09.032
Berry M, Galinier M, Delmas C, Fournier P, Desmoulin F, Turkieh A, et al. Proteomics analysis reveals IGFBP2 as a candidate diagnostic biomarker for heart failure. IJC Metab Endocr 2015;6:5-12. doi:10.1016/j.ijcme.2014.11.003
Vergaro G, Emdin M, Iervasi A, Zyw L, Gabutti A, Poletti R, et al. Prognostic value of plasma renin activity in heart failure. Am J Cardiol 2011;108:246-251. doi:10.1016/j.amjcard.2011.03.034
El-Armouche A, Zolk O, Rau T, Eschenhagen T. Inhibitory G-proteins and their role in desensitization of the adenylyl cyclase pathway in heart failure. Cardiovasc Res 2003;60:478-487. doi:10.1016/j.cardiores.2003.09.014
Mehel H, Emons J, Vettel C, Wittköpper K, Seppelt D, Dewenter M, et al. Phosphodiesterase-2 is up-regulated in human failing hearts and blunts β-adrenergic responses in cardiomyocytes. J Am Coll Cardiol 2013;62:1596-1606. doi:10.1016/j.jacc.2013.05.057
Magnussen C, Blankenberg S. Biomarkers for heart failure: Small molecules with high clinical relevance. J Intern Med 2018;283:530-543. doi:10.1111/joim.12756
Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003;24:1735-1743. doi:10.1016/j.ehj.2003.07.005
Luchner A, Burnett JC, Jougasaki M, Hense HW, Heid IM, Muders F, et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens 2000;18:1121-1128. doi:10.1097/00004872-200018080-00018
Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PWF, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: The Framingham heart study. JAMA 2002;288:1252-1259. doi:10.1001/jama.288.10.1252
de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet Lond Engl 2003;362:316-322. doi:10.1016/S0140-6736(03)13976-1
Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003;108:833-838. doi:10.1161/01.CIR.0000084543.79097.34
Chow SL, Maisel AS, Anand I, Bozkurt B, de Boer RA, Felker GM, et al. Role of biomarkers for the prevention, assessment, and management of heart failure: A scientific statement from the American Heart Association. Circulation 2017;135:e1054-e1091. doi:10.1161/CIR.0000000000000490
Markousis-Mavrogenis G, Tromp J, Ouwerkerk W, Devalaraja M, Anker SD, Cleland JG, et al. The clinical significance of interleukin-6 in heart failure: Results from the BIOSTAT-CHF study. Eur J Heart Fail 2019;21:965-973. doi:10.1002/ejhf.1482
Heymans S, Eriksson U, Lehtonen J, Cooper LT. The quest for new approaches in myocarditis and inflammatory cardiomyopathy. J Am Coll Cardiol 2016;68:2348-2364. doi:10.1016/j.jacc.2016.09.937
Tschöpe C, Ammirati E, Bozkurt B, Caforio ALP, Cooper LT, Felix SB, et al. Myocarditis and inflammatory cardiomyopathy: Current evidence and future directions. Nat Rev Cardiol 2021;18:169-193. doi:10.1038/s41569-020-00435-x
Bondue A, Arbustini E, Bianco A, Ciccarelli M, Dawson D, De Rosa M, et al. Complex roads from genotype to phenotype in dilated cardiomyopathy: Scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. Cardiovasc Res 2018;114:1287-1303. doi:10.1093/cvr/cvy122
Mazzarotto F, Tayal U, Buchan RJ, Midwinter W, Wilk A, Whiffin N, et al. Reevaluating the genetic contribution of monogenic dilated cardiomyopathy. Circulation 2020;141:387-398. doi:10.1161/CIRCULATIONAHA.119.037661
LeWinter MM, Granzier HL. Cardiac titin and heart disease. J Cardiovasc Pharmacol 2014;63:207-212. doi:10.1097/FJC.0000000000000007
Herman DS, Lam L, Taylor MRG, Wang L, Teekakirikul P, Christodoulou D, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med 2012;366:619-628. doi:10.1056/NEJMoa1110186
Jansweijer JA, Nieuwhof K, Russo F, Hoorntje ET, Jongbloed JDH, Lekanne Deprez RH, et al. Truncating titin mutations are associated with a mild and treatable form of dilated cardiomyopathy. Eur J Heart Fail 2017;19:512-521. doi:10.1002/ejhf.673
Akhtar MM, Lorenzini M, Cicerchia M, Ochoa JP, Hey TM, Sabater Molina M, et al. Clinical phenotypes and prognosis of dilated cardiomyopathy caused by truncating variants in the TTN gene. Circ Heart Fail 2020;13:e006832. doi:10.1161/CIRCHEARTFAILURE.119.006832
Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, Lunde IG, Wakimoto H, Smith AM, et al. Genetic variants associated with cancer therapy-induced cardiomyopathy. Circulation 2019;140:31-41. doi:10.1161/CIRCULATIONAHA.118.037934
Ware JS, Amor-Salamanca A, Tayal U, Govind R, Serrano I, Salazar-Mendiguchía J, et al. Genetic etiology for alcohol-induced cardiac toxicity. J Am Coll Cardiol 2018;71:2293-2302. doi:10.1016/j.jacc.2018.03.462
Ware JS, Li J, Mazaika E, Yasso CM, DeSouza T, Cappola TP, et al. Shared genetic predisposition in peripartum and dilated cardiomyopathies. N Engl J Med 2016;374:233-241. doi:10.1056/NEJMoa1505517
Hasselberg NE, Haland TF, Saberniak J, Brekke PH, Berge KE, Leren TP, et al. Lamin A/C cardiomyopathy: Young onset, high penetrance, and frequent need for heart transplantation. Eur Heart J 2018;39:853-860. doi:10.1093/eurheartj/ehx596
van der Zwaag PA, van Rijsingen IAW, Asimaki A, Jongbloed JDH, van Veldhuisen DJ, Wiesfeld ACP, et al. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: Evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur J Heart Fail 2012;14:1199-1207. doi:10.1093/eurjhf/hfs119
Ortiz-Genga MF, Cuenca S, Dal Ferro M, Zorio E, Salgado-Aranda R, Climent V, et al. Truncating FLNC mutations are associated with high-risk dilated and arrhythmogenic cardiomyopathies. J Am Coll Cardiol 2016;68:2440-2451. doi:10.1016/j.jacc.2016.09.927
Hey TM, Rasmussen TB, Madsen T, Aagaard MM, Harbo M, Mølgaard H, et al. Pathogenic RBM20-variants are associated with a severe disease expression in male patients with dilated cardiomyopathy. Circ Heart Fail 2019;12:e005700. doi:10.1161/CIRCHEARTFAILURE.118.005700
van den Hoogenhof MMG, Beqqali A, Amin AS, van der Made I, Aufiero S, Khan MAF, et al. RBM20 mutations induce an arrhythmogenic dilated cardiomyopathy related to disturbed calcium handling. Circulation 2018;138:1330-1342. doi:10.1161/CIRCULATIONAHA.117.031947
Wilde AAM, Semsarian C, Márquez MF, Sepehri Shamloo A, Ackerman MJ, Ashley EA, et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol 2022;euac030.
Towbin JA, McKenna WJ, Abrams DJ, Ackerman MJ, Calkins H, Darrieux FCC, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm 2019;16:e301-e372. doi:10.1016/j.hrthm.2019.05.007
Fomin A, Gärtner A, Cyganek L, Tiburcy M, Tuleta I, Wellers L, et al. Truncated titin proteins and titin haploinsufficiency are targets for functional recovery in human cardiomyopathy due to TTN mutations. Sci Transl Med 2021;13:eabd3079. doi:10.1126/scitranslmed.abd3079